Endonovo Therapeutics Inc (ENDV)

[rockman213]

Endonovo Therapeutics, Inc. (OTCQB: ENDV)

Market Cap: $7.3M, current share price: .028

ENDV is an innovative biotechnology company implementing a bioelectronic approach to regenerative medicine. They are addressing several healthcare trends with their electroceutical platform, which is a non-invasive, non-implantable device for treating inflammatory conditions in vital organs. Through the innovative research at ENDV, they are addressing most of the major healthcare trends by developing therapies to treat the aging population and addressing obesity and the complications that it entails, such as peripheral artery disease, heart disease, diabetic kidney disease and non-alcoholic steatohepatitis (NASH). Additionally, ENDV is working to address global diseases, kidney disease, and organ failure.

Tracking ENDV and their work in research and development (R&D) is something anyone interested in healthcare or biotech stocks should do. As their research correlates and ebbs and flows with healthcare trends. Some highlights regarding ENDV's R&D are below:
Initial target is the treatment of ischemic heart disease and peripheral artery disease
Several currently planned studies have been developed targeting inflammatory pathologies of renal origin which include: acute kidney injury and diabetic nephropathy.
Only biotech currently developing a non-invasive, non-pharmacological approach for the treatment of NASH, an inflammatory condition in the liver due to a buildup of fat that can lead to cirrhosis and liver failure if left untreated
As ENDV moves forward and inches closer to announcing the results of their pre-clinical studies across their diverse technology platform, you'll want to stay up-to-date with their successes.